AtriCure, Inc. $ATRC Shares Sold by Algert Global LLC

Key Points

• Algert Global cut its AtriCure stake by 65.1% in the second quarter, selling 26,560 shares and retaining 14,239 shares worth approximately $398,000. Institutional investors and hedge funds collectively own 99.11% of the company.
• AtriCure insiders sold 53,616 shares worth about $2.15 million over the past three months, including notable sales by directors Maggie Yuen and Karen Prange.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and a $49.89 price target. The company reported quarterly revenue of $153.6 million and EPS of $0.18, exceeding revenue expectations.

Algert Global LLC lowered its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 65.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,239 shares of the medical device company's stock after selling 26,560 shares during the period. Algert Global LLC's holdings in AtriCure were worth $398,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of AtriCure by 1.0% during the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company's stock worth $2,700,000 after purchasing an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company's stock valued at $908,000 after buying an additional 1,230 shares during the period. Goldman Sachs Group Inc. boosted its position in AtriCure by 1.0% during the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company's stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC boosted its position in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company's stock worth $3,254,000 after acquiring an additional 87,553 shares during the last quarter. Finally, Strs Ohio purchased a new stake in AtriCure in the 1st quarter worth approximately $158,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the sale, the director directly owned 14,015 shares in the company, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karen Prange sold 3,564 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares of the company's stock, valued at $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 53,616 shares of company stock worth $2,149,994. Corporate insiders own 4.00% of the company's stock.

Wall Street Analyst Weigh In

ATRC has been the subject of a number of recent analyst reports. BTIG Research lifted their price objective on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, August 24th. Zacks Research lowered AtriCure from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 24th. Piper Sandler lifted their price target on AtriCure from $50.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 19th. Finally, UBS Group decreased their target price on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, AtriCure presently has an average rating of "Moderate Buy" and a consensus price target of $49.89.

AtriCure Price Performance

Shares of AtriCure stock opened at $48.54 on Monday. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $49.98. The company has a market capitalization of $2.47 billion, a PE ratio of 231.15 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The business has a 50-day moving average of $37.89 and a 200-day moving average of $32.22.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.